Eating Disorders News and Research

Latest Eating Disorders News and Research

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

19 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009

Millennium's sNDA to be reviewed by the FDA

The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA1 trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

3 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

Eating Recovery Center releases white paper on referral practices

Eating Recovery Center (www.eatingrecoverycenter.com), a behavioral hospital focused on comprehensive and sustainable treatment of eating disorders, today released a white paper, "Eating Recovery Center's Report on Referral Practices: Recent Research Reveals Trends in the Process of Referrals for Eating Disordered Patients."

2 Sep 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

Insight Psychological Centers to open a living facility for women coping with eating disorders

On September 1, the founders of Insight Psychological Centers will open Millennium Place, a cozy urban living facility for women coping with eating disorders. Millennium Place, LLC is the first transitional housing program in Chicago developed specifically for women with anorexia, bulimia and binge eating disorders.

28 Aug 2009

The Renfrew Center joins forces with AKASA for treating women with eating disorders

The Renfrew Center, the country’s leading authority on eating disorder treatment and research, recently announced the expansion of its services into Central America through a partnership with the Guatemala-based AKASA treatment center. The first center in Central America exclusively dedicated to the treatment of women with eating disorders, AKASA now operates as an independent affiliate of The Renfrew Center.

27 Aug 2009

New website launched by Eating Disorder Hope to provide a comprehensive resource on eating disorders

Millions of Americans suffer from eating disorders and many don't know where to turn to for help. Jacquelyn Ekern, a licensed counselor and founder of Eating Disorder Hope, launched the site, www.eatingdisorderhope.com, to provide a comprehensive resource for support, referrals and education about eating disorders.

26 Aug 2009

Diet pills, alcohol, caffeine, nicotine, amphetamines and cocaine abused by patients with eating disorders

Between 11 and 13 million people in the U.S. have eating disorders and at least one million will die from their disorder. It is not unusual for women and girls struggling with eating disorders to either abuse or become dependent on over-the-counter substances.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Running and addiction

Although exercise is good for your health, extreme exercise may be physically addicting. Rats given a drug that produces withdrawal in heroin addicts went into withdrawal after running excessively in exercise wheels, according to new research. Rats that ran the hardest had the most severe withdrawal symptoms.

17 Aug 2009

Psychology of weight regulation - eating, exercise, and body image

Childhood obesity has quadrupled in the last 40 years, which may mean today's children become the first generation to have a shorter lifespan than their parents, a leading obesity expert told the American Psychological Association on Saturday.

9 Aug 2009

Dietary supplements with steroids pose health risks

Three cases of patients suffering from the adverse affects of steroid-enriched dietary supplements have been reported by researchers at Henry Ford Hospital.

4 Aug 2009

Neural correlates of impaired cognitive-behavioral flexibility in anorexia nervosa

Anorexic patients drastically reduce food intake and are often not capable of changing their behavior. This can lead to life-threatening weight loss. Using MRI technology, scientists at Heidelberg University Hospital have discovered for the first time processes in brain metabolism that explain this disturbed eating behavior.

3 Aug 2009

Risk factors of disordered eating in overweight youth identified

University of Minnesota Project Eating Among Teens (EAT) researchers have identified factors that may increase overweight adolescents' risk of engaging in extreme weight control behaviors such as self-induced vomiting, the use of diet pills, laxatives, and diuretics, as well as binge eating.

31 Jul 2009

Stress implicated in anorexia nervosa and obesity

An academic at the University of Hertfordshire is leading a research team to explore how emotions, habits and stress can cause people difficulties in controlling their weight.

21 Jul 2009

Eating Disorders News and Research

Latest Eating Disorders News and Research

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Millennium's sNDA for VELCADE granted priority review by the FDA

Merck update on the status of telcagepant clinical development programs

FDA approves Supplemental New Drug Application for DOXIL

Millennium's sNDA to be reviewed by the FDA

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Eating Recovery Center releases white paper on referral practices

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Insight Psychological Centers to open a living facility for women coping with eating disorders

The Renfrew Center joins forces with AKASA for treating women with eating disorders

New website launched by Eating Disorder Hope to provide a comprehensive resource on eating disorders

Diet pills, alcohol, caffeine, nicotine, amphetamines and cocaine abused by patients with eating disorders

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Running and addiction

Psychology of weight regulation - eating, exercise, and body image

Dietary supplements with steroids pose health risks

Neural correlates of impaired cognitive-behavioral flexibility in anorexia nervosa

Risk factors of disordered eating in overweight youth identified

Stress implicated in anorexia nervosa and obesity

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Eating Disorders News and Research

Latest Eating Disorders News and Research

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in